ArticleBMC oral health2025
Inhibition of CXCR4 suppresses bone invasion in a murine model of oral squamous cell carcinoma.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundC-X-C chemokine receptor type 4 (CXCR4) plays a significant role in the tumor microenvironment of oral squamous cell carcinoma (OSCC), but its specific function in bone invasion remains poorly understood.
methodsBioinformatic analysis of the GSE30784 dataset and Gene Ontology enrichment were performed. The role of CXCR4 was investigated using an in vivo model where poorly differentiated HSC-3 cells were inoculated into the heads of T cell-deficient female BALB/c nude mice (6 weeks old). Mice were treated systemically with the CXCR4 inhibitor AMD3100 (100 µl per dose, every other day for one week) or a PBS control (n = 3 per group). Bone invasion was defined as radiographically and histologically confirmed osteolysis of the bone. It was quantified by micro-computed tomography (micro-CT) analysis of parameters including Bone Mineral Density (BMD) and Bone Volume/Tissue Volume (BV/TV). Osteoclast activation and the expression of CXCR4 and epithelial-mesenchymal transition (EMT) markers were assessed by histochemical and immunohistochemical staining.
resultsCXCR4 was upregulated in OSCC tissues and associated with biological processes critical for bone invasion, including cell motility and migration. In the murine model, AMD3100 treatment significantly suppressed mandibular bone destruction. Micro-CT analysis revealed a significant increase in BMD and BV/TV, and a decrease in Bone Surface/Bone Volume (BS/BV) in the treated group compared to controls (all p < 0.05). Histological evaluation showed that AMD3100 reduced bone resorption and decreased the number of TRAP-positive osteoclasts by approximately 80% (p < 0.01). Furthermore, immunohistochemical staining demonstrated that AMD3100 not only inhibited CXCR4 but also significantly downregulated the expression of the pro-invasive marker MMP9 and the EMT regulators Snail and Vimentin, with IHC scores reduced by 30–50% (p < 0.05).
conclusionsOur findings demonstrate that inhibition of CXCR4 suppresses bone invasion by OSCC through dual mechanisms: inhibiting osteoclast activation and impairing the EMT process in cancer cells. These results suggest that targeting CXCR4 represents a promising therapeutic strategy to prevent bone destruction in patients with OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.